Irish biotech firm Heart Metabolics snags $20 mln Series A funds
Heart Metabolics said Thursday that it has closed $20 million in Series A funding. The investors were venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill. Based in Dublin, Ireland, Heart Metabolics is a biotech firm focused on developing treatments for cardio-metabolic diseases.
17 April 2014•3 mins read
